| 摘要 |
Biomarkers, methods, assays, and kits are provided for predicting the progression of Barrett esophagus in a subject to esophageal cancer. The method can therefore also be used to select the appropriate treatment for a subject diagnosed with Barrett esophagus. Disclosed are methods for predicting the progression of Barrett esophagus in a subject to esophageal cancer. The method can therefore also be used to select the appropriate treatment for a subject diagnosed with Barrett esophagus. For example, the disclosed biomarkers, methods, assays, and kits can be used to predict the benefit of surgery, laser treatment, radiofrequency ablation, radiation therapy, chemotherapy, or any combination thereof for a subject diagnosed with Barrett esophagus based on whether they are predicted to progress to esophageal cancer. |
| 主权项 |
1. A method for predicting the progression of Barrett esophagus in a subject to esophageal cancer, comprising
a) determining in a biological sample from the subject expression levels of one or more miRNA selected from the group consisting of hsa-miR-143-3p, hsa-miR-145-5p, hsa-miR-150-5p, hsa-miR-199a-3p+/hsa-miR-199b-3p, hsa-miR-126-3p, hsa-miR-142-3p, hsa-miR-4516, hsa-miR-125b-5p, hsa-miR-26a-5p, hsa-let-7e-5p, hsa-miR-26b-5p, hsa-miR-130a-3p, hsa-miR-199b-5p, hsa-miR-100-5p, hsa-miR-29b-3p, hsa-miR-30a-5p, hsa-miR-30b-5p, hsa-miR-199a-5p, hsa-miR-223-3p, hsa-miR-342-3p, hsa-miR-361-5p, hsa-miR-1915-3p, hsa-miR-497-5p, hsa-miR-34a-5p, hsa-miR-125a-5p, hsa-miR-195-5p, hsa-miR-374b-5p, hsa-miR-376a-3p, hsa-miR-423-5p, hsa-miR-720, hsa-miR-132-3p, hsa-miR-4508, and hsa-miR-3195; and b) comparing the miRNA expression levels to control values;wherein elevated expression levels of the miRNA is an indication that the Barrett esophagus is likely to progress to esophageal cancer. |
